Hutchison China Ltd(HMDCF) News

Date	Title
Nov 9	HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
Aug 3	HUTCHMED (China) First Half 2023 Earnings: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)